RxDoctor Payments Data

Joseph Cipriano

Family · Vineland, NJNPI 1922558683

Payments from drug & device makers

$4,382in general payments, 2019–2025

Across 276 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$813
  • AbbVie$275
  • Merck$185
  • Johnson & Johnson$171
  • Janssen Products, LP$99
  • plus $376 from 11 others

What the payments were for

  • Food & beverage$4,28398%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,382 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala47$181,355
DovatoDolutegravir Sodium/Lamivudine35$101,142
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$52,024
DescovyEmtricitabine/Tenofov Alafenam14$30,147
DelstrigoDoravirine/Lamivu/Tenofov Diso11$28,879
TivicayDolutegravir Sodium12$26,482
OzempicSemaglutide14$16,437
TradjentaLinagliptin17$10,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,282
EliquisApixaban12$8,123
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$7,644
Breo ElliptaFluticasone/Vilanterol11$5,165
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,396
HumalogInsulin Lispro11$3,511
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$813$263,52674 claims
Viiv Healthcare CompanyDovato, Tivicay$2,464$127,62447 claims
MerckDelstrigo$185$28,87911 claims
Novo NordiskOzempic$38$16,43714 claims
GSKTrelegy Ellipta, Breo Ellipta$60$13,44724 claims
PfizerEliquis$17$8,12312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →